Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/118356
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShanmuganathan, N.en
dc.contributor.authorHughes, T.en
dc.date.issued2018en
dc.identifier.citationHematology, 2018; 2018(1):168-176en
dc.identifier.issn1520-4391en
dc.identifier.issn1520-4383en
dc.identifier.urihttp://hdl.handle.net/2440/118356-
dc.descriptionThis article was selected by the Blood and Hematology 2018 American Society of Hematology Education Program editors for concurrent submission to Blood and Hematology 2018. It is reprinted from Blood 2018, Volume 132.en
dc.description.abstractWith the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the goal and expectation for most patients. More recently, treatment-free remission (TFR) has entered mainstream practice and is increasingly being adopted as the main goal of therapy. This therapeutic shift not only influences TKI selection but also, has necessitated the refinement and dissemination of highly sensitive and accurate molecular monitoring techniques. Measurement of BCR-ABL1 messenger RNA expression through reverse transcription quantitative polymerase chain reaction, reported according to the International Scale, has become the primary tool for response assessment in CML. Achieving specific time-dependent molecular milestones, as defined by global therapeutic guidelines, has been established as critical in maximizing optimal outcomes while identifying patients at risk of therapy failure. Depth and duration of a deep molecular response have become the new therapeutic targets in patients considered for TFR. Consequently, molecular monitoring in CML has become even more critical to ongoing response assessment, identifying patients with TKI resistance and poor drug adherence, and enabling TFR to be attempted safely and effectively.en
dc.description.statementofresponsibilityNaranie Shanmuganathan, Timothy P. Hughesen
dc.language.isoenen
dc.publisherAmerican Society of Hematologyen
dc.rights© 2018 by The American Society of Hematology: all rights reserved.en
dc.subjectChronic myeloid-leukemiaen
dc.titleMolecular monitoring in CML: how deep? How often? How should it influence therapy?en
dc.typeJournal articleen
dc.identifier.rmid0030108902en
dc.identifier.doi10.1182/asheducation-2018.1.168en
dc.identifier.pubid452776-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidShanmuganathan, N. [0000-0001-5895-8797]en
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.